SCHEMBL6964392

SCHEMBL6964392

COc1ccc(S(=O)(=O)NC2(C(=O)O)CCCC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 9/20 0.56
MMP13 P45452 9/20 0.56
USP2 O75604 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MMP2 P08253 3/20 0.51
MMP9 P14780 3/20 0.51
MMP8 P22894 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
LMNA P02545 1/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
CYP1A2 P05177 1/20 0.46
MMP3 P08254 2/20 0.45
MMP7 P09237 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5674362 0.99 USP2 (0.56) MMP1MMP13USP2HTTSMN1; SMN2
SCHEMBL643982 0.87 MMP1 (0.55) MMP1MMP13USP2HTTSMN1; SMN2
SCHEMBL6962839 0.86 MMP1 (0.74) MMP1MMP13MMP2MMP9MMP8
SCHEMBL6960331 0.85 MMP1 (0.72) MMP1MMP13MMP2MMP9MMP8
SCHEMBL7251813 0.84 MMP13 (0.55) MMP1MMP13MMP2MMP9MMP8
SCHEMBL7066448 0.83 MMP13 (0.62) MMP1MMP13USP2HTTSMN1; SMN2
SCHEMBL7410002 0.82 MMP13 (0.48) MMP1MMP13USP2MMP2MMP9
SCHEMBL7065804 0.82 SMN1; SMN2 (0.60) MMP1MMP13USP2HTTSMN1; SMN2
SCHEMBL6869740 0.82 MMP1 (0.77) MMP1MMP13USP2HTTSMN1; SMN2
SCHEMBL27565303 0.82 MMP1 (0.50) MMP1MMP13HTTSMN1; SMN2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0977733-B1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PROD INC (US) 2003-09-03 EP disclosed
US-20020006920-A1 Arylsulfonylamino hydroxamic acid derivatives ROBINSON RALPH PELTON (US) 2002-01-17 US disclosed
US-6303636-B1 FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR PFIZER INC 2001-10-16 US disclosed
EP-0977733-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-02-09 EP disclosed
WO-1998033768-A1 ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006920-A1 Arylsulfonylamino hydroxamic acid derivatives MMP8, MMP1, MMP10 MMP1 2/4885MMP13 18/4885USP2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.